Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1989 Dec;60(6):928–933. doi: 10.1038/bjc.1989.392

Recombinant alpha 2 interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: a prospective randomised trial.

C L Lai 1, P C Wu 1, A S Lok 1, H J Lin 1, H Ngan 1, J Y Lau 1, H T Chung 1, M M Ng 1, E K Yeoh 1, M Arnold 1
PMCID: PMC2247256  PMID: 2557881

Abstract

In a prospective trial of 75 Chinese patients with histologically proven inoperable hepatocellular carcinoma (HCC), 25 patients were randomised to receive doxorubicin 60-75 mg m-2 intravenously once every 3 weeks, 25 to receive recombinant alpha 2 interferon (rIFN) (Roferon) 9-18 x 10(6) IU m-2 intramuscularly (i.m.) daily and 25 to receive rIFN 25-50 x 10(6) IU m-2 i.m. three times weekly. Patients were switched to the other drug if: (a) there was progressive disease after 12 weeks, (b) unacceptable toxicity developed and (c) they had received a total of 500 mg m-2 of doxorubicin. Six patients had switching over of therapy, three on doxorubicin and three on rIFN. In the remaining 69 patients on single drug therapy, the median survival rate of patients on doxorubicin and rIFN was 4.8 and 8.3 weeks respectively (P = ns.). rIFN induced tumour regression of 25-50% in 12% of patients and of over 50% in 10% of patients. When compared with doxorubicin, rIFN was associated with more tumour regression (P = 0.00199) and less progressive tumours (P = 0.00017). It caused less prolonged and less severe marrow suppression (P = 0.01217), and had significantly less fatal complications than doxorubicin (P = 0.01383). Doxorubicin caused fatal complications due to cardiotoxicity and neutropenia in 25% of patients. rIFN was associated with fatal complications due to dementia and renal failure in 3.8% of patients. In the treatment of inoperable HCC, rIFN is superior to doxorubicin in causing more tumour regression, less serious marrow suppression and less fatal complications.

Full text

PDF
928

Images in this article

930Figure 2
on p.930
930Figure 3
on p.930

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adams F., Quesada J. R., Gutterman J. U. Neuropsychiatric manifestations of human leukocyte interferon therapy in patients with cancer. JAMA. 1984 Aug 17;252(7):938–941. [PubMed] [Google Scholar]
  2. Chlebowski R. T., Brzechwa-Adjukiewicz A., Cowden A., Block J. B., Tong M., Chan K. K. Doxorubicin (75 mg/m2) for hepatocellular carcinoma: clinical and pharmacokinetic results. Cancer Treat Rep. 1984 Mar;68(3):487–491. [PubMed] [Google Scholar]
  3. Di Bisceglie A. M., Rustgi V. K., Hoofnagle J. H., Dusheiko G. M., Lotze M. T. NIH conference. Hepatocellular carcinoma. Ann Intern Med. 1988 Mar;108(3):390–401. doi: 10.7326/0003-4819-108-3-390. [DOI] [PubMed] [Google Scholar]
  4. Dunk A. A., Ikeda T., Pignatelli M., Thomas H. C. Human lymphoblastoid interferon. In vitro and in vivo studies in hepatocellular carcinoma. J Hepatol. 1986;2(3):419–429. doi: 10.1016/s0168-8278(86)80053-8. [DOI] [PubMed] [Google Scholar]
  5. Henderson I. C., Frei E., 3rd Adriamycin cardiotoxicity. Am Heart J. 1980 May;99(5):671–674. doi: 10.1016/0002-8703(80)90743-7. [DOI] [PubMed] [Google Scholar]
  6. Lai C. L., Lam K. C., Wong K. P., Wu P. C., Todd D. Clinical features of hepatocellular carcinoma: review of 211 patients in Hong Kong. Cancer. 1981 Jun 1;47(11):2746–2755. doi: 10.1002/1097-0142(19810601)47:11<2746::aid-cncr2820471134>3.0.co;2-k. [DOI] [PubMed] [Google Scholar]
  7. Lai C. L., Wu P. C., Chan G. C., Lok A. S., Lin H. J. Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer. 1988 Aug 1;62(3):479–483. doi: 10.1002/1097-0142(19880801)62:3<479::aid-cncr2820620306>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
  8. Lok A. S., Lai C. L. alpha-Fetoprotein monitoring in Chinese patients with chronic hepatitis B virus infection: role in the early detection of hepatocellular carcinoma. Hepatology. 1989 Jan;9(1):110–115. doi: 10.1002/hep.1840090119. [DOI] [PubMed] [Google Scholar]
  9. London W. T. Primary hepatocellular carcinoma--etiology, pathogenesis, and prevention. Hum Pathol. 1981 Dec;12(12):1085–1097. doi: 10.1016/s0046-8177(81)80329-2. [DOI] [PubMed] [Google Scholar]
  10. McDonald E. M., Mann A. H., Thomas H. C. Interferons as mediators of psychiatric morbidity. An investigation in a trial of recombinant alpha-interferon in hepatitis-B carriers. Lancet. 1987 Nov 21;2(8569):1175–1178. doi: 10.1016/s0140-6736(87)91319-5. [DOI] [PubMed] [Google Scholar]
  11. Nair P. V., Tong M. J., Kempf R., Co R., Lee S. D., Venturi C. L. Clinical, serologic, and immunologic effects of human leukocyte interferon in HBsAg-positive primary hepatocellular carcinoma. Cancer. 1985 Sep 1;56(5):1018–1022. doi: 10.1002/1097-0142(19850901)56:5<1018::aid-cncr2820560507>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  12. Sachs E., Di Bisceglie A. M., Dusheiko G. M., Song E., Lyons S. F., Schoub B. D., Kew M. C. Treatment of hepatocellular carcinoma with recombinant leucocyte interferon: a pilot study. Br J Cancer. 1985 Jul;52(1):105–109. doi: 10.1038/bjc.1985.156. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES